Manufacturing
CellCure Neurosciences is Lineage’s in-house cGMP manufacturing facility
A subsidiary of Lineage Cell Therapeutics, Inc.*
Advancing a cell therapy from basic research to bedside medicine requires cGMP-compliant & commercially feasible CTSDPs (cell-type-specific differentiation protocols).
CellCure Neurosciences Ltd., a Lineage subsidiary which began at the Hadassah Medical Center in Israel, has developed cell growth, expansion, and reproducibility protocols required to manufacture specialized cell types on a commercial scale.
In-house cGMP Manufacturing Capabilities
- Source cell characterization, banking and versatile expansion systems
- Differentiation process development; culture conditions, systems, optimization of differentiation cues (growth factor selection, timing, etc.)
- Analytical method development for process control and product release
- Scale-up modalities, substrates, harvesting protocols
- Enhancements; RNA genetic modification (optional), various expression systems
- Clinically compatible post-production processing
Our manufacturing is backed by an extensive IP portfolio covering processes, products, and methods of use.
*Lineage Cell Therapeutics, Inc. owns 94% of the outstanding shares of CellCure Neurosciences Ltd.